Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
Authors
Tuba Nur Gide
Melanoma Institute Australia, Central Clinical School, Faculty of Medicine, The University of Sydney, Sydney, Australia
Tuba Nur Gide, Camelia Quek, Jason Madore, Alexander M. Menzies, Rebecca Dent, Matteo S. Carlino, Alex Guminski, Robyn Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Prognostic and Predictive Markers
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 51)
DOI
10.1200/JCO.2017.35.7_suppl.51
Abstract #
51
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
First Author: Jose Antonio Lopez Guerrero
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2020 ASCO Virtual Scientific Program
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.
First Author: Yuval Shaked
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Role for immune checkpoint blockade in BRCA2-mutant prostate cancer.
First Author: Anshuman Panda